  Purpose. Patients with advanced cancer may undergo multiple lines of
treatment, switching therapies as their disease progresses. Motivated by a
study of metastatic prostate cancer, we develop a microsimulation framework to
study therapy sequence. Methods. We propose a discrete-time state transition
model to study two lines of anti-cancer therapy. Based on digitized published
progression-free survival (PFS) and overall survival (OS) curves, we infer
event types (progression or death), and estimate transition probabilities using
cumulative incidence functions with competing risks. Our model incorporates
within-patient dependence over time, such that response to first-line therapy
informs subsequent event probabilities. Parameters governing the degree of
within-patient dependence can be used to calibrate the model-based results to
those of a target trial. We demonstrate these methods in a study of two therapy
sequences for metastatic prostate cancer, where Docetaxel (DCT) and Abiraterone
Acetate (AA) are both appropriate for use in either first or second line
treatment. We assess costs, Quality-Adjusted Life Years (QALYs) and Incremental
Cost Effectiveness Ratio (ICER) for two treatment strategies: DCT then AA vs AA
then DCT. Results. Using digitized survival curves from relevant clinical
trials, we identified 8.6-13.9% of PFS times that should be categorized as
deaths, allowing for estimation of cumulative incidence functions. Models
assuming within-patient independence overestimated OS time, corrected with our
calibration approach. Correction resulted in meaningful changes in the
difference in QALYs between treatment strategies (0.07 vs 0.15) and the ICER
(-\$76,836/QALY vs -\$21,030/QALY). Conclusions. Microsimulation models can be
successfully used to study cost-effectiveness of therapy sequences, taking care
to account correctly for within-patient dependence.
